Hepatacellular carcinoma
Conditions
Interventions
FOLFOX:Hepatic artery perfusion FOLFOX
Combined therapy:Hepatic artery perfusion FOLFOX + other drugs or radiofrequency ablation
Sponsors
Sun Yat-sen University Cancer Center
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-75 years old; 2. Pathological diagnosis as HCC, or clinical imaging diagnosis as HCC; 3. At least one measurable lesion (according to mrecist); 4. Estimated survival time >=4 weeks; 5. ECOG Performance Status 0-2; 6. Child-Pugh Score A or B; 7. Leukocyte number >=3.0x10^9/l; 8. Platelet count >=50 x10^9 / L; 9. ALT and AST <=5 ULN; 10. Serum creatinine <=1.5 ULN; 11. If there is hypertension, blood pressure can be controlled; if there is diabetes, blood sugar can be controlled; 12. If you have received unexpected medication, you need to stop medication for more than 4 weeks; 13. No iodine allergy; 14. Understand the condition and sign the informed consent voluntarily
Exclusion criteria
Exclusion criteria: 1. Be allergic to the drugs which will be used; 2. If FOLFOX will be used, the patient has taken oxaliplatin, fluorouracil or folic acid; 3. Liver transplantation patients; 4. Pregnant or lactating women; 5. Uncontrollable ascites; 6. Gastroesophageal varices lead to gastrointestinal bleeding; 7. Serious hepatoencephalopathy or kidney disease, which makes it impossible to operate; 8. Serious heart disease, such as coronary artery disease, arrhythmia requiring treatment, etc; 9. There are other confirmed malignant tumors in the primary site; 10. Any unstable condition or situation that may endanger the safety and compliance of the patient.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ORR;PFS; | — |
Countries
China
Contacts
Public ContactMing Zhao
Sun Yat-sen University Cancer Center
Outcome results
None listed